Darya Lucas
Associate Attorney
O: 651.430.7150
M: 651.374.9015
Darya Lucas advises medical device and pharmaceutical companies on FDA regulatory strategy across the product life cycle. Her practice centers on FDA submissions, lifecycle compliance, and promotional review. Clients rely on her for regulatory guidance that is grounded in practical execution and aligned with development timelines and commercialization strategy.
Her approach is informed by prior in-house regulatory affairs experience within a global medical device company, along with work in clinical research and earlier legal practice. She brings an integrated understanding of how regulatory requirements intersect with product development, clinical execution, and commercial decision-making.
Darya works closely with in-house counsel, regulatory affairs, and commercial teams, often serving in a cross-functional advisory capacity. She focuses on translating regulatory requirements into clear, operational guidance that supports efficient execution and informed risk management.
Her work spans FDA submissions, promotional review, and regulatory counseling across the product life cycle. She is also engaged in product launch support, including promotional and reimbursement-related considerations, and conducts risk assessments informed by evolving enforcement trends, industry standards, and healthcare compliance expectations.
She brings a disciplined, business-oriented approach to regulatory counseling, with an emphasis on structure, documentation, and scalability. Her focus is on helping clients advance regulatory and commercial priorities with clarity while maintaining alignment between compliance obligations and business strategy.
Focus Areas
- FDA regulatory strategy for medical device and pharmaceutical companies
- FDA submissions and regulatory filings
- Product lifecycle compliance
- Promotional review and advertising compliance
- Product launch regulatory and compliance strategy
- Clinical research regulatory support
- Compliance program design and risk assessment
Representative Experience
- Supported FDA regulatory strategy and submissions for medical device and pharmaceutical products across development and commercialization stages
- Advised on promotional materials to ensure compliance with FDA advertising and labeling requirements
- Evaluated consulting, speaker, and other healthcare professional arrangements for compliance with applicable laws, regulations, and industry standards
- Provided regulatory and compliance guidance for product launches, including promotional strategy and reimbursement-related considerations
- Conducted compliance and risk assessments aligned with enforcement trends and evolving regulatory expectations
- Supported clinical research activities, including regulatory considerations for study design and execution
- Drafted and reviewed agreements involving regulatory, clinical, and compliance considerations
Differentiators
- Prior in-house regulatory affairs experience within a global medical device organization
- Experience spanning regulatory law, clinical research, and in-house compliance functions
- Ability to integrate regulatory strategy with commercial, clinical, and operational priorities
- Experience supporting product launches and commercialization strategy in highly regulated environments
- Structured, execution-focused approach to compliance, documentation, and regulatory risk management
Thought Leadership, Teaching, & Ventures
- Author, “The Peptide Boom Meets FDA Reality”
- Author, “FDA Approves New Oral GLP-1 as Scrutiny of the Market Intensifies”
- Author, “OPDP’s 2026 Untitled Letters: Early Enforcement Trends in Prescription Drug Promotion”
- Author, “Navigating FDA Promotional Compliance: TEVIMBRA and Digital Brand Assets”
- Author, “Navigating Lanham Act Risk in a Shifting Product Landscape”
- Guest Lecturer, University of Michigan School of Public Health
- Guest speaker to companies on advertising and promotional review programs and FDA compliance
- Interviewed in the press on FDA regulatory developments and compliance issues
- Speaker on regulatory and compliance topics affecting life sciences companies
Education
- J.D., Law, Mitchell Hamline School of Law
- B.A., Political Science; Minor in Biology, University of St. Thomas
Admissions & Affiliations
- Minnesota
Personal
Darya enjoys running, traveling, and listening to podcasts.
Articles, Presentations & Press
- AI Clinical Decision Support Software: The New Regulatory Reality for Digital Health and Life Sciences, Pt 2
- AI Clinical Decision Support Software: The New Regulatory Reality for Digital Health and Life Sciences, Pt 1
- FDA’s Drug Repurposing Initiative Signals a Shift in Regulatory Strategy
- The Peptide Boom Meets FDA Reality
- FDA Approves New Oral GLP-1 as Scrutiny of the Market Intensifies
- OPDP’s 2026 Untitled Letters: Early Enforcement Trends in Prescription Drug Promotion
- Navigating FDA Promotional Compliance: TEVIMBRA and Digital Brand Assets
- Navigating Lanham Act Risk in a Shifting Product Landscape